Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 18
- Registration Number
- NCT01500798
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 276
- Registration Number
- NCT01499355
- Locations
- 🇹🇭
Research Site, Patumwan, Bangkok, Thailand
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT01494701
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States
Canadian Avonex PEN Productivity Study
- Conditions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 111
- Registration Number
- NCT01489748
- Locations
- 🇨🇦
Central Contact, Burlington, Ontario, Canada
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
- Conditions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 231
- Registration Number
- NCT01485003
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 4734
- Registration Number
- NCT01480063
- Locations
- 🇪🇸
Site Research, Bilbao, Vizcaya, Spain
🇪🇸Research site, San Cristobal de La laguna, Tenerife, Spain
🇨🇦Reasearch Center, London, Ontario, Canada
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 901
- Registration Number
- NCT01480076
- Locations
- 🇬🇧
Research Site, London, United Kingdom
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 133
- Registration Number
- NCT01462318
- Locations
- 🇵🇱
Research Site, Krakow, Poland
Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 71
- Registration Number
- NCT01453426
- Locations
- 🇨🇳
Research Site, Hong Kong, Hong Kong, China
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 106
- Registration Number
- NCT01440101
- Locations
- 🇯🇵
Research Site, Yokohama, Japan